目的:探讨年轻女性乳腺癌(18～35岁)患者的临床特点和预后。方法:回顾性分析176例年轻女性乳腺癌患者的肿瘤大小、病理类型、TNM分期、淋巴结转移率、雌、孕激素受体及c-erbB-2表达,与同期就诊的242例中老年女性乳腺癌患者(>35岁)相比较。结果:年轻组中位就诊时间10.35个月明显晚于中老年组6.27个月;两组在肿瘤大小及病理类型分布上差异无统计学意义,P>0.05;组织学分级中:年轻组Ⅰ级和Ⅲ级的比例分别为7.19%和59.88%,中老年组为23.04%和40.00%,两组比较差异有统计学意义,P<0.05,年轻组腋窝淋巴结以及内乳淋巴结的转移率分别为69.62%和37.63%,均明显高于中老年组51.38%和16.87%,两组比较差异有统计学意义,P<0.05。年轻组ER、PR和c-erbB-2阳性率分别为30.68%、31.82%和67.05%,与中老年组65.29%、56.61%和29.75%相比,差异有统计学意义,P<0.05。结论:年轻乳腺癌具有临床分期晚,组织学分级高,淋巴结转移率高,激素受体阳性率低,c-erbB-2阳性率高等特点,且复发转移率高,预后差。 Objective: To investigate the clinical features and prognosis of young female breast cancer (18 ~ 35 years old). Methods: Tumor size, pathological type, TNM stage, lymph node metastasis, estrogen and progesterone receptor and c-erbB-2 expression in 176 young women with breast cancer were retrospectively analyzed. Compared with 242 middle-aged and older women with breast cancer Cancer patients (> 35 years) compared. Results: The median treatment time of young group was 10.35 months later than that of middle aged group (6.27 months). There was no significant difference between the two groups in the distribution of tumor size and pathological type (P> 0.05) And Ⅲ grade were 7.19% and 59.88% in the middle-aged group and 23.04% and 40.00% in the middle-aged and elderly group, respectively. There was significant difference between the two groups (P <0.05). The metastatic rates of axillary lymph nodes and internal mammary nodes in young group were 69.62 % And 37.63%, respectively, were significantly higher than 51.38% and 16.87% of middle-aged and elderly patients, the difference between the two groups was statistically significant, P <0.05. The positive rates of ER, PR and c-erbB-2 in young patients were 30.68%, 31.82% and 67.05%, respectively, which were significantly different from 65.29%, 56.61% and 29.75% in middle-aged and elderly patients, P <0.05. Conclusion: Young breast cancer has the characteristics of late clinical stage, high histological grade, high lymph node metastasis rate, low positive rate of hormone receptor and high c-erbB-2 positive rate, with high recurrence and metastasis rate and poor prognosis.